Leukemia Research
Volume 27, Issue 7 , Pages 661-669 , July 2003

Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia

  • Srdan Verstovsek

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, P.O. Box 428, Houston, TX 77030, USA
    • ,
  • Scott Lunin

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, P.O. Box 428, Houston, TX 77030, USA
    • ,
  • Hagop Kantarjian

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, P.O. Box 428, Houston, TX 77030, USA
    • ,
  • Taghi Manshouri

      Affiliations

    • Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, P.O. Box 72, Houston, TX 77030-4095, USA
    • ,
  • Stefan Faderl

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, P.O. Box 428, Houston, TX 77030, USA
    • ,
  • Jorge Cortes

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, P.O. Box 428, Houston, TX 77030, USA
    • ,
  • Francis Giles

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, P.O. Box 428, Houston, TX 77030, USA
    • ,
  • Maher Albitar

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, P.O. Box 428, Houston, TX 77030, USA
    • Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, P.O. Box 72, Houston, TX 77030-4095, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-713-794-1292; fax: +1-713-794-1800.

Received 22 August 2002 ,Accepted 24 October 2002.

References 

  1. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 1971;285:1182–1186
  2. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 1990;82:4–6 [editorial]
  3. Folkman J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 1992;3:65–71
  4. Gimbrone MA, Leapman SB, Cotran RS, Folkman J. Tumor angiogenesis: iris neovascularization at a distance from experimental intraocular tumors. J. Natl. Cancer Inst. 1973;50:219–228
  5. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989;339:58–61
  6. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur. J. Cancer. 1996;32A:2451–2460
  7. Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am. J. Pathol. 2000;157:15–19
  8. Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, et al.  Angiogenesis in myelodysplastic syndromes. Br. J. Cancer. 1999;81:1398–1401
  9. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, et al.  Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol. 1994;87:503–508
  10. Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo F, et al.  Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin’s lymphomas. Br. J. Cancer. 1999;79:965–970
  11. Perez-Ataye AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol. 1997;150:815–821
  12. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 2000;95:309–313
  13. Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, et al.  Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:2637–2644
  14. Aguayo A, Kantarjian H, Manshouri T, et al.  Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240–2245
  15. Bussolino F, Albini A, Camussi G, Presta M, Viglietto G, Ziche M, et al.  Role of soluble mediators in angiogenesis. Eur. J. Cancer. 1996;32A:2401–2412
  16. Ferrara N. Vascular endothelial growth factor. Eur. J. Cancer. 1996;32A:2413–2422
  17. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv. Cancer Res. 1992;59:115–165
  18. Gualandris A, Urbinati C, Rusnati M, Ziche M, Presta M. Interaction of high-molecular-weight basic fibroblast growth factor with endothelium: biological activity and intracellular fate of human recombinant M(r) 24,000 bFGF. J. Cell Physiol. 1994;161:149–159
  19. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc. Natl. Acad. Sci. U.S.A. 1986;83:7297–7301
  20. Mignatti P, Tsuboi R, Robbins E, Rifkin DB. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J. Cell Biol. 1989;108:671–682
  21. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–1309
  22. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, et al.  Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246:1309–1312
  23. Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, et al.  Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 1996;93:2576–2581
  24. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, et al.  A novel vascular endothelial growth factor, VEGF-C, is a ligand for the flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15:1751
  25. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, et al.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (flk1) and VEGF receptor 3 (flt4). Proc. Natl. Acad. Sci. U.S.A. 1998;95:548–553
  26. Yamada Y, Nezu J, Shimane M, Hirata Y. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics. 1997;42:483–488
  27. Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 1998;273:31273–31282
  28. Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn. J. Cancer Res. 1994;85:1045–1049
  29. O’Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res. 1995;55:510–513
  30. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55:3964–3968
  31. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, et al.  Quantification of angiogenesis in solid human tumors: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer. 1996;32A:2474–2484
  32. Gasparini G. Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vicenza studies. Eur. J. Cancer. 1996;32A:2485–2493
  33. Chung YS, Maeda K, Sowa M. Prognostic value of angiogenesis in gastro-intestinal tumours. Eur. J. Cancer. 1996;32A:2501–2505
  34. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 1992;84:1875–1887
  35. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 1993;143:401–409
  36. Graham CH, Rivers J, Kerbel RS, Stankiewicz KS, White WL. Extent of vascularization as a prognostic indicator in thin (<0.76 mm) malignant melanomas. Am. J. Pathol. 1994;145:510–514
  37. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ. Tumor angiogenesis in advanced stage ovarian carcinoma. Am. J. Pathol. 1995;147:33–41
  38. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin’s lymphoma. Blood. 1997;90:3167–3172
  39. Aguayo A, Estey E, Kantarjian H, Manshouri T, Gidel C, Keating M, et al.  Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94:3717–3721
  40. Aguayo A, O’Brien S, Keating M, Manshouri T, Gidel C, Barlogie B, et al.  Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood. 2000;96:768–770
  41. Hayashibara T, Fujimoto T, Miyanishi T, Yamada Y, Maita T, Kamihira S, et al.  Vascular endothelial growth factor at high plasma levels is associated with extranodal involvement in adult T cell leukemia patients. Leukemia. 1999;13:1634–1635 [letter]
  42. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr. Top. Microbiol. Immunol. 1999;237:1–30
  43. Shibuya M, Ito N, Claesson-Welsh L. Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr. Top. Microbiol. Immunol. 1999;237:59–83
  44. Veikkola T, Alitalo K. VEGFs. Semin. Cancer Biol. 1999;9:211–220
  45. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000;60:203–212
  46. Xie B, Tam NN, Tsao SW, Wong YC. Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat. Br. J. Cancer. 1999;81:1335–1343
  47. Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF, et al.  Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab. Invest. 1996;74:1105–1115
  48. Takanami I, Tanaka F, Hashizume T, Kodaira S. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res. 1997;17:2811–2814
  49. Hahn D, Simak R, Steiner GE, Handisurya A, Susani M, Marberger M. Expression of the VEGF-receptor flt-1 in benign. J. Urol. 2000;164:506–510
  50. Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, et al.  Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870–1875
  51. Katoh O, Tauchi H, Kawaishi K, Kimura A, Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res. 1995;55:687–692
  52. Ratajczak MZ, Ratajczak J, Machalinski B, Majka M, Marlicz W, Carter A, et al.  Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PlGF) in regulating human haemopoietic cell growth. Br. J. Haematol. 1998;103:969–979
  53. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999;59:728–733
  54. Saclarides TJ, Speziale NJ, Drab E, Szeluga DJ, Rubin DB. Tumor angiogenesis and rectal carcinoma. Dis. Colon Rectum. 1994;37:921–926
  55. Kim DK, Watson RC, Pahnke LD, Fortner JG. Tumor vascularity as a prognostic factor for hepatic tumors. Ann. Surg. 1977;185:31–34
  56. Revesz L, Siracka E. A morphometric study of vascularization in uterine cervix cancers. Cytometry. 1984;5:442–444
  57. Srivastava A, Hughes LE, Woodcock JP, Shedden EJ. The significance of blood flow in cutaneous malignant melanoma demonstrated by Doppler flowmetry. Eur. J. Surg. Oncol. 1986;12:13–18
  58. Revesz L, Siracka E, Balmukhanov S. Tumor vascularity: its possible prognostic and therapeutic value. Strahlenther. Onkol. 1986;162:639–641
  59. Van Hoef ME, Knox WF, Dhesi SS, Howell A, Schor AM. Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur. J. Cancer. 1993;8:1141–1145
  60. Vesalainen S, Lipponen P, Talja M, Alhava E, Syrjanen K. Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma. Anticancer Res. 1994;14:709–714
  61. Maeda K, Chung YS, Ogawa Y, Ko T, Ogawa M, Onoda N, et al.  Expression of vascular endothelial cell growth factor as a predictor of recurrence in gastric carcinoma. Gan To Kagaku Ryoho. 1995;22:699–701
  62. Dirix LY, Vermeulen PB, Hubens G, Benoy I, Martin M, De Pooter C, et al.  Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann. Oncol. 1996;7:843–848
  63. Crew JP, O’Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D, et al.  Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997;57:5281–5285
  64. Hartenbach EM, Olson TA, Goswitz JJ, Mohanraj D, Twiggs LB, Carson LF, et al.  Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett. 1997;121:169–175
  65. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Giles FJ, Rogers A, et al.  Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood. 2002;99:2265–2267

PII: S0145-2126(02)00275-8

doi: 10.1016/S0145-2126(02)00275-8

Leukemia Research
Volume 27, Issue 7 , Pages 661-669 , July 2003

Article Tools

* Image Usage & Resolution